SciBX
Science-Business eXchange

THE DISTILLERY

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Pancreatic cancer	DNA methyltransferase	*In vitro* and mouse studies suggest hypomethylating agents could help treat pancreatic ductal adenocarcinoma (PDAC). In a mouse model of aggressive, stroma-rich PDAC, the demethylating agent Dacogen decitabine decreased tumor burden and increased survival compared with vehicle control. Next steps include testing Dacogen plus therapeutic cytokines and immunotherapy. Astex Pharmaceuticals Inc., Eisai Co. Ltd. and Johnson & Johnson market Dacogen, a DNA methyltransferase inhibitor, to treat acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).	Patent and licensing status unavailable	Shakya, R. *et al. Cancer Res.*; published online Nov. 29, 2012; doi:10.1158/0008-5472.CAN-12-1880 **Contact:** Benjamin Tycko, Columbia University, New York, N.Y. e-mail: bt12@columbia.edu

SciBX 6(1); doi:10.1038/scibx.2013.10
Published online Jan. 10, 2013